コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 mportant role for the gut microbiome in anti-tumor immunity.
2 implanted tumors and displayed enhanced anti-tumor immunity.
3 est in harnessing these receptors to augment tumor immunity.
4 plicates in cancer cells while inducing anti-tumor immunity.
5 w insights into the regulation of human anti-tumor immunity.
6 vating TLR4 agonist capable of inducing anti-tumor immunity.
7 immune responses that are required for anti-tumor immunity.
8 s Treg instability locally and restores anti-tumor immunity.
9 hophysiological context: suppression of anti-tumor immunity.
10 of autoimmunity and the suppression of anti-tumor immunity.
11 iltrating T cells results in diminished anti-tumor immunity.
12 responses, as well as their contribution to tumor immunity.
13 latory T cells (Tregs) are a barrier to anti-tumor immunity.
14 in restraining PD1 expression and promoting tumor immunity.
15 cular pathway to inhibit CD8 T-cell-mediated tumor immunity.
16 in D signaling in humans could suppress anti-tumor immunity.
17 1alpha/VEGF-A axis is an essential aspect of tumor immunity.
18 ory Siglecs that can potentially dampen anti-tumor immunity.
19 ntigens that can potentially elicit specific tumor immunity.
20 enuation as well as the facilitation of anti-tumor immunity.
21 s and their ability to induce efficient anti-tumor immunity.
22 grammed into indispensable mediators of anti-tumor immunity.
23 icity and its role in the activation of anti-tumor immunity.
24 the tumor microenvironment while empowering tumor immunity.
25 xis mediates suppression of T-cell-dependent tumor immunity.
26 isease and graft rejection and promotes anti-tumor immunity.
27 riasis, but pDCs are also involved in (anti-)tumor immunity.
28 ve review of Eph receptors in the context of tumor immunity.
29 on ligands and thereby negated adaptive anti-tumor immunity.
30 f tumor antigens and thereby stimulates anti-tumor immunity.
31 play complex and poorly understood roles in tumor immunity.
32 ole of the Hippo pathway in suppressing anti-tumor immunity.
33 ing, and impairment of T cell-dependent anti-tumor immunity.
34 promote T cell self-renewal and enhance anti-tumor immunity.
35 o reveal a role for zinc homeostasis in anti-tumor immunity.
36 cells pose a major barrier to effective anti-tumor immunity.
37 alphabeta T cell receptor (TCR) mediate anti-tumor immunity.
38 paradoxical and poorly understood effects on tumor immunity.
39 ic niche formation and the induction of anti-tumor immunity.
40 o be a major contributor to compromised anti-tumor immunity.
41 ting T cell function, autoimmunity, and anti-tumor immunity.
42 T cell function during autoimmunity and anti-tumor immunity.
43 tant tools to investigate carcinogenesis and tumor immunity.
44 requirements to elicit and maintain durable tumor immunity.
45 ory apoptosis reduced priming efficiency and tumor immunity.
46 ing ongoing (rather than generating de novo) tumor immunity.
47 se availability to T cells, suppressing anti-tumor immunity.
48 entral roles in infection, autoimmunity, and tumor immunity.
49 mor-infiltrating dendritic cells blunts anti-tumor immunity.
50 re important targets of T cell-mediated anti-tumor immunity.
51 n cancer (OvCa) progression by blunting anti-tumor immunity.
52 ant melanoma, by impeding IgG1-mediated anti-tumor immunity.
53 cancer cells, as well as in suppressing anti-tumor immunity.
54 issues function in parallel to restrict anti-tumor immunity.
55 rovide therapeutic benefit by enhancing anti-tumor immunity.
56 umor microenvironment that can suppress anti-tumor immunity.
57 FOXP3-specific T cell responses and enhances tumor immunity.
58 the mechanism by which OX40 may impact anti-tumor immunity.
59 Rs and play important roles in microbial and tumor immunity.
60 tion, tumor angiogenesis, and suppression of tumor immunity.
61 to reverse this phenomenon and promote anti-tumor immunity.
62 s prevented T-cell tolerization and restored tumor immunity.
63 deregulate the immune response and favor pro-tumor immunity.
64 ing involvement of SOCS3 in autoimmunity and tumor immunity.
65 membrane target antigens using humoral anti-tumor immunity.
66 to the tumor microenvironment restrains anti-tumor immunity.
67 indicates that B cells are involved in anti-tumor immunity.
68 enesis pathway is sufficient to restore anti-tumor immunity.
69 vaccine adjuvants for infectious disease and tumor immunity.
70 ating Th cell development, inflammation, and tumor immunity.
71 RCA function to disable T cell-mediated anti-tumor immunity.
72 g the generation of innate and adaptive anti-tumor immunity.
73 regulating the balance between pro- and anti-tumor immunity.
74 e bottleneck, which precludes efficient anti-tumor immunity.
75 pid vessel loss, which does not support anti-tumor immunity.
76 ophages (TAMs) may have an important role in tumor immunity.
77 t therapeutic B cell depletion would enhance tumor immunity.
78 D8(+) T cells, which are key players in anti-tumor immunity.
79 asthma, and allergic responses as well as in tumor immunity.
80 of immunosuppression hinder productive anti-tumor immunity.
81 t NK-DC interactions without compromising NK tumor immunity.
82 l memory phenotype associated with long-term tumor immunity.
83 cts in allergic airway inflammation and anti-tumor immunity.
84 and Th17 cells may play a protective role in tumor immunity.
85 partial loss of TcR-I effector functions and tumor immunity.
86 ent to tumors and in regulation of effective tumor immunity.
87 ole for this receptor in HSP70.PC-F-mediated tumor immunity.
88 eroidogenesis in T lymphocytes to evade anti-tumor immunity.
89 ive immune pathways important for protective tumor immunity.
90 5 repression is critical for modulating anti-tumor immunity.
91 T cells have diverse tolerogenic effects on tumor immunity.
92 g by tumor cells in obese mice improves anti-tumor immunity.
93 endowed with a strong potential to regulate tumor immunity.
94 the PD-L1 checkpoint inhibitor augments anti-tumor immunity.
95 ate lymphocytes important for anti-viral and tumor immunity.
96 can be administered recombinantly to improve tumor immunity.
97 le for mirn23a miRNAs in macrophage-mediated tumor immunity.
98 breast TME and unleashes host adaptive anti-tumor immunity.
99 al success by blocking amplification of anti-tumor immunity.
100 better strategies to restore protective anti-tumor immunity.
101 oma progression was mediated by altered anti-tumor immunity.
102 substantial room for engineering better anti-tumor immunity.
103 ith a focus on how these interactions affect tumor immunity.
104 t negatively regulates T-cell activation and tumor immunity.
105 nses through DCs, thereby strengthening anti-tumor immunity.
106 on of CD8(+) TILs that limits effective anti-tumor immunity.
107 negative regulator of T-cell activation and tumor immunity.
108 r cells is essential for dMMR-triggered anti-tumor immunity.
109 lapping but non-redundant regulation of anti-tumor immunity.
110 t immunosuppressive functions hindering anti-tumor immunity.
111 ween cancer-associated inflammation and anti-tumor immunity.
112 X receptors, previously shown to boost anti-tumor immunity(4), exhibited therapeutic efficacy in APO
116 unotherapy for cancer is capable of inducing tumor immunity, an antitumor effect that results from en
117 s are important and potent mediators of anti-tumor immunity and adoptive transfer of specific CD4(+)
119 In this study, we tested the balance between tumor immunity and autoimmunity in neu-transgenic BALB N
120 en-specific cells increased vaccine-elicited tumor immunity and autoimmunity, but a threshold was rea
123 appreciated roles for IL-35 in limiting anti-tumor immunity and contributing to T cell dysfunction in
124 es critical cellular interactions regulating tumor immunity and defines mechanisms underlying myeloid
125 omplexity of functions for IFN-gamma in anti-tumor immunity and demonstrate that intratumor heterogen
126 suppressive mechanisms used by MDSC to block tumor immunity and describes the mechanisms by which inf
127 e of molecular diversity as a driver of anti-tumor immunity and discuss how these factors can be prob
128 data show that the anti-OX40-enhancement of tumor immunity and effector T cell numbers is decreased
129 ng pathways, can contribute to decrease anti-tumor immunity and enhance cell proliferation and oncoge
130 ss responses to reinvigorate endogenous anti-tumor immunity and enhance the efficacy of various forms
132 ypothesized that integrin beta3 could affect tumor immunity and evaluated tumors in mice with deletio
133 ombination with FAK, can drive enhanced anti-tumor immunity and even complete regression of murine tu
134 ro-inflammatory environment may curtail anti-tumor immunity and favor cancer initiation and progressi
135 late with the development of productive anti-tumor immunity and greater efficacy of PD1 immunotherapy
137 (+)CD8(+) T cells can promote effective anti-tumor immunity and implicate PTPN2 in immune cells as an
138 ased CD226 surface expression, enhanced anti-tumor immunity and improved efficacy of immune checkpoin
139 tion of parameters underlying effective anti-tumor immunity and is available to the research communit
140 eraction by monoclonal antibodies stimulates tumor immunity and is therapeutic against established mo
141 thers in early development, can unleash anti-tumor immunity and mediate durable cancer regressions.
142 red around the genetic foundations governing tumor immunity and molecular determinants associated wit
143 These results suggest a role for IL-9 in tumor immunity and offer insight into potential therapeu
144 oregulatory axis with broad implications for tumor immunity and other immunological and disease setti
147 ss the local and systemic effects of VEGF on tumor immunity and propose a potentially translatable st
148 s increases innate sensing and adaptive anti-tumor immunity and provide strong rationales for combini
149 ex-dependent, B7-H1-dependent differences in tumor immunity and response to immunotherapy in a hormon
150 enriched in Rnf5(-/-) mice, establishes anti-tumor immunity and restricts melanoma growth in germ-fre
151 intracellular checkpoint in NK cell-mediated tumor immunity and suggest possibilities for new cancer
152 h other check-point inhibitors enhances anti-tumor immunity and suppresses tumor growth in several pr
154 n different cells and their cross-talk shape tumor immunity and therapy efficacy in patients with can
156 -origin cells that are potent suppressors of tumor immunity and therefore a significant impediment to
157 e for applying this approach to survey liver tumor immunity and to stratify patients for immune-based
158 of Rnf5(-/-) and WT mice abolishes the anti-tumor immunity and tumor inhibition phenotype, whereas t
159 d that Cu- and Zn-AMSs markedly induced anti-tumor-immunity and enhanced CD4(+) and CD8(+) T cell pop
161 on in regulating autoimmunity and tolerance, tumor immunity, and host defense against intracellular p
164 hus, leptin can provide metabolic support to tumor immunity, and oncolytic viruses represent a platfo
167 r role in tumor-associated blood vessels and tumor immunity, and provide an update on mTOR inhibitors
168 sion, anemic T cell tumor infiltration, poor tumor immunity, and shortened host survival in many huma
169 hanistic insights into the role of TR-CD4 in tumor immunity, and suggest that approaches to utilize T
170 erived cells, enhances T cell-dependent anti-tumor immunity, and synergizes with immune checkpoint bl
171 on, the roles of different NRs in modulating tumor immunity, and the biological features of immune ce
172 of this T cell subset, their function during tumor immunity, and the means to utilize their unique ki
175 ect susceptibility to infection or graft-vs.-tumor immunity are hampered by the lack of a physiologic
178 of effector immune responses is pivotal for tumor immunity as well as for successful anticancer vacc
179 utoimmune skin depigmentation (vitiligo) and tumor immunity, because they are expressed by both benig
180 ry NKG2D receptor on T and NK cells mediates tumor immunity but can also promote local and systemic i
182 regs is necessary to abrogate suppression of tumor immunity, but a third cell, the type I NKT cell, d
183 re innate immune cells that are important in tumor immunity, but also have the ability to modulate th
184 their pro-cancer activities and unleash anti-tumor immunity, but efforts to accomplish this are nonsp
185 ed on how tumor missense mutations can drive tumor immunity, but frameshift mutations have the potent
186 ockade of PD-1 enhances T cell-mediated anti-tumor immunity, but many patients do not respond and a s
187 umor-specific rejection antigens for natural tumor immunity, but we know remarkably little about T-ce
188 ttern on malignant cells potentially affects tumor immunity by directly influencing interactions with
189 ic cells (cDC1s) control anti-viral and anti-tumor immunity by inducing antigen-specific cytotoxic CD
191 d may lead to a new strategy to restore anti-tumor immunity by inhibiting pathways of force-generatio
193 its inhibition enhances T cell migration and tumor immunity by preserving functional chemokine CXCL10
194 D-1/PD-L1 blockade enhanced the amplitude of tumor immunity by reprogramming suppressive and stimulat
197 ptide ligands in order to induce strong anti-tumor immunity capable of breaking tolerance toward thes
198 ulation of the immune system to amplify anti-tumor immunity carries the risk of developing autoimmune
199 t defense against microbial infections, anti-tumor immunity, cellular senescence, autophagy, and auto
200 ed by a native tumor-antigen boost, improves tumor immunity compared with T cells elicited by the sam
201 data suggest the importance of Th17 cells to tumor immunity, conclusions regarding the functional rol
204 e have therefore demonstrated that effective tumor immunity correlates with the presence of endogenou
205 restoration of TTP expression enhances anti-tumor immunity dependent on degradation of PD-L1 mRNA.
207 to the general mechanisms of vaccine-induced tumor immunity directed toward tumors bearing distinct t
208 al killer (NK) cells are critical for innate tumor immunity due to their specialized ability to recog
210 idence shows that SWI/SNF complexes regulate tumor immunity; for instance, the loss of PBRM1, another
211 ure immune system, we detect measurable anti-tumor immunity from very early stages, which is driven b
212 ss and invasion programs while inducing anti-tumor immunity genes and may therefore restrain malignan
214 cape of a tumor shapes and is shaped by anti-tumor immunity has not been systematically explored.
219 cells may not have direct effector roles in tumor immunity, impaired T cell activation, and enhanced
221 ount their multi-faceted roles in regulating tumor immunity in addition to their growth-regulatory fu
222 0 Tag protein immunization mounted effective tumor immunity in an established experimental pulmonary
223 ontrol of TH9 differentiation regulated anti-tumor immunity in an experimental melanoma-bearing model
224 nt study, we investigated the development of tumor immunity in an HLA-A0201(+) MM patient who achieve
225 ers T cell glycolytic metabolism and affects tumor immunity in cancer patients remains a question.
227 poietic 5-lipoxygenase (5LO) that may impact tumor immunity in development of colon cancer has not be
228 etion of CD8(+) T lymphocytes did not impair tumor immunity in either immune phase and resulted in th
230 have demonstrated augmented T cell-mediated tumor immunity in genetically B cell-deficient mice, sug
231 g this approach into the clinic might rescue tumor immunity in immune-desert landscapes.See related a
237 s may lead to novel therapies enhancing anti-tumor immunity in the context of aging or metabolic dysf
238 ed tumors, this combination compromised anti-tumor immunity in the low tumor burden (LTB) state in pr
239 ntibody blockade of Siglec-15 amplifies anti-tumor immunity in the TME and inhibits tumor growth in s
240 ll activation, antibody production, and anti-tumor immunity in vivo, and m(6)A modification abrogates
241 ocultured T cells in vitro, compromises anti-tumor immunity in vivo, and reduces anti-tumor efficacy
243 filtrating myeloid cells (TIM) that suppress tumor immunity, including M2 macrophages and myeloid-der
244 the immune components necessary for systemic tumor immunity induced upon immunization with plasmid DN
248 Understanding the mechanisms underlying anti-tumor immunity is pivotal for improving immune-based can
254 rn the overall effects of Hippo signaling on tumor immunity, it is clear that Hippo signaling functio
256 nce of CD4 T cells, development of long-term tumor immunity (memory) was severely compromised as refl
259 microenvironment and their contributions to tumor immunity or tolerance are incompletely understood.
260 ype represent novel checkpoint inhibitors in tumor immunity, potent tools for the eradication of chro
261 s immunomodulatory activities to induce anti-tumor immunity predict the suppression of tumor growth.
273 challenge resulted in greater attenuation of tumor immunity than observed with selective depletion of
275 f MerTK-mediated phagocytosis mobilizes anti-tumor immunity through a mechanism that involves the tra
277 n of additional therapies that modulate anti-tumor immunity through effects on T cells, myeloid cells
278 h17 cells may contribute to protective human tumor immunity through inducing Th1-type chemokines and
280 t instead impede development of desired anti-tumor immunity, thus providing synergistic effects betwe
282 for tumor-derived HSP70 in facilitating anti-tumor immunity to limit tumor growth and highlight the p
284 he regulation of processes ranging from anti-tumor immunity to the adjuvant action of aluminum hydrox
285 m and split tolerance, with implications for tumor immunity, transplantation, autoimmunity, and repro
289 of tumor-derived IL-35 in tumorigenesis and tumor immunity, we generated IL-35-producing plasmacytom
291 , complete tumor regression and long-lasting tumor immunity were observed, still without adverse effe
292 NA expression for genes associated with anti-tumor immunity were obtained from the invasive breast ca
293 4(+) T cells and may therefore contribute to tumor immunity, whereas a peptide overlapping the juncti
294 es tumor immunogenicity and potentiates anti-tumor immunity, which has implications for cancer immuno
296 Hematopoietic Progenitor Kinase 1 (HPK1) in tumor immunity will be reviewed, with special emphasis o
297 d CD4(+) T cells, promotes and enhances anti-tumor immunity with limited success on large tumors in m
299 immune cell components that lead to systemic tumor immunity within an experimental pulmonary metastat